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Abstract
Background: It is estimated that over 190 million bisphosphonates have been prescribed worldwide. But this drug 
can produce adverse effects, of which osteonecrosis of the jaw and severe hypocalcemia are the most serious. It 
is evident that bisphosphonate administration affects multiple and diverse biochemical mediators related to bone 
metabolism. Material and Methods: This review of literature investigates four basic parameters in patients treated 
with bisphosphonates - parathyroid hormone (PTH), bisphosphonates, vitamin D, calcium, and jaw osteonecrosis 
- which are fundamental for assessing bone metabolism and so the efficacy and correct use of the drug. The imba-
lances generated by vitamin D and calcium deficiencies, together with their multiple systemic repercussions, have 
been widely researched but the outcomes of these imbalances in relation to bisphosphonate administration are not 
well known, and some research has indicated that they may be associated with osteonecrosis of the jaw (ONJ).  
Results: The present review set out to explain the functioning of bone metabolism, the importance of different 
chemical mediators, the imbalances produced by incorrect use of this drug, in order to forewarn against the pos-
sible relation of these parameters with ONJ, whose physiopathology remains unknown. Conclusions: Medical and 
dental clinics should keep detailed anamneses of the use of vitamin D and calcium supplements, as it is of vital 
importance to maintain their correct levels in blood, given that these are related to ONJ as well as other adverse 
effects; this procedure is also necessary in order to ensure the correct use of the drug.
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Introduction 
Bisphosphonates are potent inhibitors of osteoclast 
activation, and the first choice for treating pathologies 
that affect bone metabolism such as osteoporosis and 
Paget’s disease. They are also used to treat malignant 
tumors such as multiple myeloma or other tumors with 
bone metastasis such as prostate and breast cancers. 
According to the Advisory Task Force on Bisphospho-
nate-related Osteonecrosis of Jaws (2007), 190 mil-
lion bisphosphonates have been prescribed worldwide 
(1,2). It is said that osteoporotic bone has a negative 
balance or lack of calcium so that traditionally it has 
been treated with vitamin D and calcium supplements, 
moderate exercise, and treatment with bisphosphonates 
in cases with a risk of fracture (3,4). Generic vitamin 
D refers to both vitamin D3 (physiological in humans) 
and vitamin D2 (ultraviolet radiation). When a vitamin 
D deficiency is produced, calcium absorption decreases 
by 15% (phosphorous absorption by 60%), reducing se-
rum ionized calcium. This decrease is detected by pa-
rathyroid gland calcium sensors, which respond with an 
increase in parathyroid hormone (PTH) whose function 
is to maintain serum calcium levels, acting on the liver 
and on bone where it stimulates bone resorption. 
When the calcium supply to the organism is inade-
quate, the vitamin D hormonally active metabolite (1,25 
(OH)2D) helps maintain calcium homeostasis, acting 
on vitamin D receptors (VDR) of the osteoblasts in 
which receptor activator of nuclear factor kappa-B li-
gand (RANKL) formation is induced in a similar way 
as with PTH, so producing bone resorption for calcium 
homeostasis (3-5). When the major circulating vitamin 
D metabolite (25(OH)D) levels are very reduced a fai-
lure to produce correct calcium absorption in the intes-
tine occurs, with insufficient substrate for converting 
1,25(OH)2D, even when PTH levels are high (6,7).
For many years it was thought that the transformation 
of 25(OH)D into 1,25(OH)2D was produced only in 
the liver by the enzyme 25(OH)D-1α-hydroxylase but 
this enzyme has also been found in other tissues in the 
organism. On the basis of extensive evidence, it is un-
derstood that vitamin D is related to immune system 
regulation (8,9).
Vitamin D has other auto/paracrine functions through-
out the organism. Most tissues and cells, whether nor-
mal or neoplastic - muscle, heart, brain, blood vessels, 
breast, colon, pancreas, skin, and the immune system – 
all have VDRs and 25(OH)D activating enzymes, which 
are not regulated by PTH to synthesize 1,25(OH)2D 
(3,4). 1,25(OH)2D attaches to its VDR and regulates 
the transcription of approximately 3% of the human ge-
nome. It also modulates macrophage and lymphocyte B 
and T function. For all these reasons, 1,25(OH)2D plays 
an important role in general health (3,4).
The optimal level of vitamin D has recently been des-
cribed as follows: sufficient vitamin D concentration so 
that serum PTH levels are neither elevated nor decreased 
when vitamin D supplements are taken (10). PTH would 
appear to have a stimulating effect of bone destruction/
formation through calcium homeostasis – endocrine ac-
tions that might be described as ‘traditional’ or ‘clas-
sic.’ It has been proved that increased PTH adminis-
tered continuously has the effect of stimulating bone 
destruction. But intermittent administration stimulates 
bone formation (a process known as osteoformative or 
anabolic). The reasons for these differences remain un-
clear (3,4). PTH has a direct effect via diverse mecha-
nisms that produce this increase in osteoblast numbers, 
stimulating their differentiation and inhibiting their 
apoptosis. Among the various osteoblast-stimulating 
factors, several proteins have been identified and also 
1,25(OH)2D, which, after being synthesized in the liver 
under PTH stimulation, stimulate osteoblasts through 
endocrine action (3).
It has been indicated that hypovitaminosis D presents 
secondary hyperparathyroidism that increases bone re-
newal, losing bone mass, and in severe cases can lead to 
osteomalacia (10). The latest tendency in osteonecrosis 
treatment is the use of teriparatide (recombinant human 
PTH 1-34). One study describes how a patient with jaw 
osteonecrosis, having failed to respond to conventional 
approaches, was successfully treated with teriparatide 
(11). 
The present review set out to explain the functioning of 
bone metabolism, the importance of different chemical 
mediators, the imbalances produced by incorrect use of 
this drug, in order to forewarn against the possible rela-
tion of these parameters with ONJ, whose physiopatho-
logy remains unknown.
Material and Methods
This review was based on a literature search conducted 
in the following online databases: 
1. Medline.
2. Embase.
Key search words were used to select texts: PTH, Bis-
phosphonates, Bisphosphonate-related osteonecrosis of 
the jaw (BORNJ), ONJ, Vitamin D and Calcium. The 
search also consulted the database Uptodate® which 
located additional texts. The inclusion criteria also in-
cluded editorials, case control studies, retrospective 
studies and randomized double-blind studies related 
with bisphosphonates, vitamin D, parathyroid hormone, 
and osteonecrosis of the jaw. The search was not limited 
to human studies. We updtated publications with papers 
from January 1996 to May 2015. The articles identi-
fied were screened in duplicate (two reviewers, I.O.L.C. 
and A.A.S.). The full papers and abstracts identified 
were independently reviewed by the authors (I.O.L.C 
and A.A.S) for inclusion in this review of literature. If 
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there was lack of information provided in the abstract 
or disagreement between the reviewers, the authors re-
viewed the full text before reaching an agreement. An 
endocrinologist (M.J.S.R.) monitored all the endocrine 
aspects. M.G.J. and G.M. supervised the dental an bone 
aspects. The review was directed and supervised by 
G.G.M.
Results
The initial search identified 15 articles of which six did 
not fulfill the inclusion criteria,  leaving eight articles 
and one editorial, all published between 1996 and 2013. 
Of the articles, four were case-control studies, three 
was a retrospective studies and one randomized double-
blind studies (12-20). 
The editorial selected posed the question of whether in-
creases in PTH levels and hypocalcemia during bisphos-
phonate treatment in patients with metastatic breast 
cancer could be predisposing factors to osteonecrosis 
of the jaw. The article drew attention to the fact that 
secondary hyperparathyroidism after taking bisphos-
phonates may be related to ONJ, an issue that has never 
been investigated (12).
Three articles were found that deal with predictive PTH 
values for preventing NJO, although with contradictory 
results. A case-control study (13) found significantly lar-
ger increases in PTH among bisphosphonate patients with 
BRONJ than control subjects taking bisphosphonates but 
who did not suffer BRONJ. However, two other studies 
(14,15) did not find any significant relation between ONJ 
and PTH levels. None of these three studies took vitamin 
D and calcium supplementation into consideration.  
Another study (16) compared Group A patients in treat-
ment with Etidronate who showed vitamin D deficiency 
with Group B patients subject to the same treatment 
but presenting adequate vitamin D levels. Group A 
had significantly higher levels of PTH and lower se-
rum calcium levels one year after the start of treatment 
with Etidronate. In the Group A base sample, PTH had 
shown normal values; secondary hyperparathyroidism 
was expected as a result of hypovitaminosis D. 
A patient sample of post-menopausal women taking 
bisphosphonates and presenting increased PTH values 
were seen to obtain increased bone densitometry va-
lues, suggesting that the better the response to medica-
tion, the better the gains in bone mass. All the women 
took vitamin D and calcium supplements (17).
One study related increases in nocturnal PTH levels 
with bone mass gain (18). Patients treated with bisphos-
phonates present nocturnal peaks in PTH, which point 
to an anabolic effect of PTH. It is a well known fact 
that endocrine gland functions are related to circadian 
rhythm. All patients underwent rigorous management 
of serum calcium levels and were administered with 
supplements orally. 
The following article (19) related hypovitaminosis D 
with an increased incidence of osteonecrosis in rats; the 
osteonecrosis induced in rats is very similar to that suf-
fered by humans. The disease was provoked by means 
of injections of Zoledronate (ZOL; 35 mg/kg every 2 
weeks), extraction of a maxillary molar, and insuffi-
cient vitamin D. The prevalence of osteonecrosis was: 
Vit D (- )/ZOL: 66.7%; Vit D (- ): 0%; ZOL alone: 14.3%. 
Regarding PTH levels, when the sample was compared 
to a control group (Vit D (-), ZOL and combination of 
both) a statistically significant increase in PTH was ob-
served in the Vit D (-), an increase in the ZOL alone 
group (although without statistical significance), and a 
significant increase in the combination of Vit D (-) and 
ZOL.
Further articles selected related osteonecrosis with os-
teomalacia. One made a case-control study using his-
tomorphometric parameters by means of bone biopsies 
to analyze bone samples taken from patients medicated 
with bisphosphonates, 22 with osteonecrosis, and 21 
without (20). In this study, vitamin D supplementation 
was an exclusion criterion. 77% of patients with os-
teonecrosis suffered osteomalacia compared with 5% of 
those who did not have osteonecrosis. Given that osteo-
malacia was found almost exclusively among patients 
with osteonecrosis, it can be said that osteomalacia re-
presents a risk factor for osteonecrosis pathogenesis.
 
Discussion
The bibliography reviewed contained very few studies 
that measured all four of the basic parameters this re-
view set out to relate: PTH, Bisphosphonates, vitamin 
D, calcium and osteonecrosis of the jaw. Only one study 
(19) covered all four parameters, indicating a higher of 
incidence of osteonecrosis in rats.  In all cases, vitamin 
D deficiency produced disorders in calcium and PTH 
levels.  
Another study (20) that measured osteomalacia in pa-
tients treated with bisphosphonates, observed that 77% 
of patients with osteonecrosis suffered osteomalacia 
in comparison with 5% of control subjects without os-
teonecrosis.  
An editorial (12) posed the question of whether the in-
crease in PTH levels and hypocalcemia during bisphos-
phonate treatment in patients with metastatic breast 
cancer could be predisposing factors to ONJ. 
In other articles reviewed, vitamin D and calcium sup-
plementation was a basic inclusion criterion: - (17,18) 
- and also in the large randomized double-blind study 
performed using different antiosteoporotic drugs de-
signed to test their anti-fracture efficacy (21-25). 
A further three articles obtained contradictory results 
with regard to PTH as a predictive value of osteonecro-
sis but failed to contemplate vitamin D and calcium 
supplements in control cases (13-15). 
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In the five baseline studies carried out to test different 
antiosteoporotic drugs and their anti-fracture effects, 
calcium and vitamin D are administered to all par-
ticipants. The antifracture efficacy of bisphosphonates 
could not be demonstrated in absence of adequate le-
vels of vitamin D and calcium (21-25). Furthermore, the 
drug’s safety against hypocalcemia cannot be ensured 
unless there is an adequate supplementation as shown 
in the studies by (26-28) who described two cases of se-
vere hypocalcemia in a hypothyroid patient and another 
with occult osteomalacia. 
Generating further controversy (29), it was seen that a 
high percentage of the 38 osteoporotic, post-menopau-
sal women treated with oral bisphosphonates, undergo-
ing dental extractions, failed to meet the correct pres-
cription criteria. It might even be said that diagnosis 
had been poor, given that only 6 subjects underwent 
adequate diagnostic tests.  
According to the literature reviewed, (10) there is a 
generalized worldwide lack of vitamin D. Depending 
on the type of population studied and its cutoff point, 
the prevalence of the deficiency (< 20ng/ml) ranges bet-
ween some 30% of young people and 80% of the aged in 
care, with 50-70% prevalence among the middle-aged 
(including adults and post-menopausal women) and el-
derly not in care.
It is evident that bone metabolism is directly affected 
by bisphosphonate administration. At the same time, 
this review observed a situation of great complexity re-
garding the balance of bone metabolism due to the high 
number of mediators involved. What is clear is the need 
to maintain optimal serum levels of the different me-
diators of bone metabolism, as much for the sake of the 
correct functioning of the bisphosphonates as the pos-
sible prevention of ONJ and other adverse effects.  
The keeping of anamneses detailing daily vitamin D 
and calcium supplements in relation to bisphosphonate 
treatment could be of great importance in both, dental 
or medical practice, as this could help prevent ONJ.  In 
cases where the patient fails to take these supplements 
and the clinician has to intervene, a prior appointment 
with the endocrinologist is advisable in order to esta-
blish the state of bone metabolism and so adjust vitamin 
D, calcium and PTH levels. 
In any case, focusing on the potential risk of ONJ will 
permit the patient to make better use of bisphosphonate 
medication (30).  The lack of unanimity as to the use of 
vitamin D and C supplements among different studies is 
one of the main constraints on this review’s findings, in 
addition to the low number of articles published to date. 
For these reasons, it is clear that further studies of these 
issues are called for within the different medical fields 
involved, given the multiple functions and the systemic 
implications that these four parameters can have. In 
this way, the relations between bisphosphonates and os-
teonecrosis of the jaw represents a complex field which 
could be investigated through a wide range of research 
approaches.
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